• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Knisely JPS Yu JB Flanigan J Sznol


    2. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS. Radiosurgery for mela-noma NCT-501 metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012; 117:227-233.
    3. Nieder C, Marienhagen K, Dalhaug A, Aandahl G, Haukland E, Pawinski A. Impact of systemic treatment on survival after whole brain radio-therapy in patients with brain metastases. Med Oncol. 2014;31:927.
    4. Niwinska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of 
    5. Bourke RS, West CR, Chheda G, Tower DB. Ki-netics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intrave-nous injection in a primate. Cancer Res. 1973;33: 1735-1746.
    6. Miyajima M, Kusuhara H, Takahashi K, et al. Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. J Pharm Sci. 2013;102:3309-3319.
    8. Morikawa A, Peereboom DM, Smith QR, et al. Clinical evidence for drug penetration of
    capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013;15(suppl):514.
    9. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005;11:1669-1674.
    11. Yule SM, Price L, Pearson ADJ, Boddy AV. Cyclo-phosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res. 1997;3:1985-1992.
    WORLD NEUROSURGERY -: e1-e10, - 2019 e9
    14. von Holst H, Knochenhauer E, Blomgren H, et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien). 1990;104:13-16.
    15. Chang AY, Ying XX. Brain metastases from breast cancer and response to treatment with eribulin: a case series. Breast Cancer (Auckl). 2015;9:19-24.
    16. Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2:116-120.
    18. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol. 2006;17:200-204.
    21. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009; 11:80-91.
    22. Chalmers AJ, Jackson A, Swaisland H, et al. Re-sults of stage 1 of the oparatic trial: a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma. J Clin Oncol. 2014;32. abstract 2025.
    23. Koba T, Kijima T, Takimoto T, et al. Rapid intracranial response to osimertinib, without 
    radiotherapy, in nonsmall cell lung cancer pa-tients harboring the EGFR T790M mutation: two case reports. Medicine (Baltimore). 2017;96, e6087.
    25. Hingorani M, Dixit S, Maraveyas A. Pazopanib-induced regression of brain metastasis after whole brain palliative radiotherapy in metastatic renal cell cancer progressing on first-line sunitinib: a case report. World J Oncol. 2014;5:223-227.
    26. Jacus MO, Daryani VM, Harstead KE, et al. Phar-macokinetic properties of anticancer agents for the treatment of CNS tumors: update of the literature. Clin Pharmacokinet. 2016;55:297-311.
    27. Kimelberg HK. Tamoxifen as a powerful neuro-protectant in experimental stroke and implica-tions for human stroke therapy. Recent Pat CNS Drug Discov. 2008;3:104-108.
    28. Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.
    30. Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distri-bution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42:1292-1300.
    31. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experi-mental brain tumor. Neuro Oncol. 2004;6:300-305.
    32. Faller BA, Pandit TN. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol. 2011;5:131-144.
    33. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32: 2100-2108.